
Charles S. Fuchs, M.D. M.P.H.
Associate Professor, Department of Medicine, Harvard Medical School
Director, Gastrointestinal Malignancy Program, Dana-Farber Cancer Institute
Associate Physician, Medicine, Brigham And Women's Hospital
Associate Professor of Medicine, Medical Oncology, Dana-Farber Cancer Institute
Contact Info
Charles Fuchs
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA, 02115
Mailstop: Dana 1220
Phone: 617-632-5840
Fax: 617-632-5370
charles_fuchs@dfci.harvard.edu
Administrative Assistant
Gastrointestinal Malignancies Program
Dana-Farber Cancer Institute
Phone: 617-632-5840
lynne_anderson@dfci.harvard.edu
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA, 02115
Mailstop: Dana 1220
Phone: 617-632-5840
Fax: 617-632-5370
charles_fuchs@dfci.harvard.edu
Assistant
Lynne AndersonAdministrative Assistant
Gastrointestinal Malignancies Program
Dana-Farber Cancer Institute
Phone: 617-632-5840
lynne_anderson@dfci.harvard.edu
DF/HCC Program Affiliation
Outcomes ResearchGastrointestinal Malignancies, Leader
Cancer Epidemiology
DF/HCC Associations
DFCI, GI, Clinical Trial ChairsMember, Center Scientific Council
Principal Investigator, Gastrointestinal Cancers SPORE
Research Abstract
I currently conduct research in gastrointestinal cancer epidemiology using data from the Nurses' Health Study, the Health Professionals Follow-up Study, and the Physicians' Health Study. Assess risk factors for stomach, pancreas, and colorectal cancers. In addition to looking at the influence of diet and lifestyle, we are looking at the influence of such biomarkers as insulin-like growth factors, steroid hormones, and polymorphisms of metabolism enzymes on the risk of these cancers. I also conduct research assessing various treatment regimens and new drugs for gastrointestinal cancersPublications
- Ogino S, Hazra A, Tranah GJ, Kirkner GJ, Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Meyerhardt JA, Hunter DJ, Fuchs CS.MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer.Carcinogenesis 2
17621591 - Chan AT, Ogino S, Fuchs CS.Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2.N Engl J Med 2007 May 24;356(21):2131-2142.
17522398 - Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS.Evaluation of Markers for CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer by a Large Population-Based Sample.J Mol Diagn 2007 May 3.
17478565 - Ogino S, Kawasaki T, Kirkner G, Ogawa A, Dorfman I, Loda M, Fuchs C.Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer.J Pathol 2006 Jul 19.
16850502 - Koushik A, Tranah GJ, Ma J, Stampfer MJ, Sesso HD, Fuchs CS, Giovannucci EL, Hunter DJ.p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer.Int J Cancer 2006 May 23.
16721787 - Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Stampfer MJ, Rosner B, Speizer FE, Willett WC.Dietary fiber and the risk of colorectal cancer and adenoma in women.N Engl J Med 1999 Jan 21;340(3):169-76.
9895396 - Fuchs CS, Colditz GA, Stampfer MJ, Giovannucci EL, Hunter DJ, Rimm EB, Willett WC, Speizer FE.A prospective study of cigarette smoking and the risk of pancreatic cancer.Arch Intern Med 1996 Oct 28;156(19):2255-60.
8885826 - Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC.A prospective study of family history and the risk of colorectal cancer.N Engl J Med 1994 Dec 22;331(25):1669-74.
7969357




